Shift Bioscience raised $16 million to further its AI-driven platform
Longevity Technology - 15-Oct-2024Shift aims to treat diseases like heart issues and arthritis by addressing aging’s root causes
Daniel Ives
Founder and CEO of Shift Bioscience Limited
Daniel Ives is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based. Daniel graduated from Imperial College with a degree in biochemistry in 2009. He gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute. Daniel is the named inventor on UK patent application 1900697.2 relating to methods of novel treatment of impaired mitochondria.
Visit website: https://shiftbioscience.com/management-and-board/
See also: 
Shift Bioscience
- Biotech company targeting the root causes of aging to extend healthy lifespan
Details last updated 10-Sep-2020
Daniel Ives is also referenced in the following:
London Longevity - Reversing Ageing with AI (w/ Dr Daniel Ives)
21-Nov-2024
London Futurists event about longevity with Dr Daniel Ives (London, UK, FREE)
Longevity State Conference 2024
13-May-2024
Conference about longevity, its social changes and aging organised by Vitalism Foundation (Cofrentes, Spain)
Daniel Ives News
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
